1e
19
1
49
2
2
18
1b
1d
18
30
46
1d
2 29
1d
25
Tilo Grosser, M.D.
78
46
Adjunct Professor of Pharmacology
28
90
3
8a
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania
11
Department: Systems Pharmacology and Translational Therapeutics
4
1
b
1d
46
Contact information
6f
4
3
3
1d
6f
Department of Systems Pharmacology and Translational Therapeutics
3e University of Pennsylvania Perelman School of Medicine
30 Smilow Center for Translational Research
31 3400 Civic Center Boulevard, Building 421
3c 10th Floor, Room 103
Philadelphia, PA 19104-5158
26
3e University of Pennsylvania Perelman School of Medicine
30 Smilow Center for Translational Research
31 3400 Civic Center Boulevard, Building 421
3c 10th Floor, Room 103
Philadelphia, PA 19104-5158
30
Office: (215) 573-7600
30
97
30
Email:
tilo@pennmedicine.upenn.edu
12
tilo@pennmedicine.upenn.edu
18
Publications
23 a
3
2
29
4
b
1f
23 a
13
Education:
21 9 M.D. 15 (Medicine) c
48 Heinrich-Heine University, Düsseldorf, Germany, 1996.
21 d Dr. med. 46 (Medical research doctorate in Cardiovascular Pharmacology) c
48 Heinrich-Heine University, Düsseldorf, Germany, 1998.
c
3
3
3
3
8a
Permanent link21 9 M.D. 15 (Medicine) c
48 Heinrich-Heine University, Düsseldorf, Germany, 1996.
21 d Dr. med. 46 (Medical research doctorate in Cardiovascular Pharmacology) c
48 Heinrich-Heine University, Düsseldorf, Germany, 1998.
c
2 29
21
1e
1d
24
5e
26 29
27
Description of Research Expertise
329 Dr. Grosser's lab studies the human biology of inflammation and the translational therapeutics of lipid mediators. He is interested in understanding how the benefit of drugs targeting lipid mediators (e.g. NSAIDs) can be exploited while managing or avoiding their adverse effects. If this can be established for NSAIDs, where there is a subtle trade-off between benefit and risk at the population level (but less subtle at the individual level), it may serve as a general paradigm for the personalization of other commonly used classes of drugs. Dr. Grosser conducts human deep-phenotyping trials designed to elucidate genomic and non-genomic variability in the response to drugs. He studies molecular mechanisms using genomics, proteomics, lipidomics approaches in humans and model organisms.26 29
23
1a1 Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs. Clin Pharmacol Ther 108 (2): 191-200, 2020 Notes: https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf.
1e8 Theken KN, Hersh EV, Lahens NF, Lee HM, Granquist EJ, Giannakopoulos H, Levin LM, Secreto-Dankanich SA, Grant GR, Detre JA, FitzGerald GA, Grosser T* (Co-Corresponding Author), Farrar JT*: Variability in the Analgesic Response to Ibuprofen Is Associated With Cyclooxygenase Activation in Inflammatory Pain. Clin Pharmacol Ther 106(3): 632-641, 2019 Notes: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1446.
10d Theken KN, Grosser T: Weight-adjusted aspirin for cardiovascular prevention. Lancet 392(10145): 361-362, 2018 Notes: https://www.sciencedirect.com/science/article/pii/S0140673618313072?via%3Dihub.
b6 Grosser T, Woolf CJ, FitzGerald GA: Time for nonaddictive relief of pain. Science 355(6329): 1026-1027, 2017.
149 Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Lei L, Liang J, Moore JE, Cryer B, Marathi U.: Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 69(6): 603-612, 2017.
184 Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T: Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 111(47): 16830-5, 2014 Notes: http://www.pnas.org/content/111/47/16830.long.
143 Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA: Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin. Circulation 127(3): 377-85, 2013 Notes: http://circ.ahajournals.org/content/127/3/377.full.
154 Lucitt MB, Price TS, Pizarro A, Wu W, Yocum AK, Seiler C, Pack MA, Blair IA, FitzGerald GA, Grosser T: Analysis of the zebrafish proteome during embryonic development. Mol Cell Proteomics 7(5): 981-94, 2008 Notes: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2401336/
149 Fries S*, Grosser T* [* Co-First Authors], Price TS, Lawson JA, Kapoor S, DeMarco S, Pletcher MT, Wiltshire T, FitzGerald GA: Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130: 55-64, 2006.
2c
7
1d
1f
Selected Publications
e9 Lordan R, FitzGerald GA, Grosser T: Reopening schools during COVID-19. Science 369: 1146, 2020 Notes: https://science.sciencemag.org/content/369/6508/1146.long.1a1 Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs. Clin Pharmacol Ther 108 (2): 191-200, 2020 Notes: https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf.
1e8 Theken KN, Hersh EV, Lahens NF, Lee HM, Granquist EJ, Giannakopoulos H, Levin LM, Secreto-Dankanich SA, Grant GR, Detre JA, FitzGerald GA, Grosser T* (Co-Corresponding Author), Farrar JT*: Variability in the Analgesic Response to Ibuprofen Is Associated With Cyclooxygenase Activation in Inflammatory Pain. Clin Pharmacol Ther 106(3): 632-641, 2019 Notes: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1446.
10d Theken KN, Grosser T: Weight-adjusted aspirin for cardiovascular prevention. Lancet 392(10145): 361-362, 2018 Notes: https://www.sciencedirect.com/science/article/pii/S0140673618313072?via%3Dihub.
b6 Grosser T, Woolf CJ, FitzGerald GA: Time for nonaddictive relief of pain. Science 355(6329): 1026-1027, 2017.
149 Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Lei L, Liang J, Moore JE, Cryer B, Marathi U.: Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 69(6): 603-612, 2017.
184 Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T: Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 111(47): 16830-5, 2014 Notes: http://www.pnas.org/content/111/47/16830.long.
143 Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA: Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin. Circulation 127(3): 377-85, 2013 Notes: http://circ.ahajournals.org/content/127/3/377.full.
154 Lucitt MB, Price TS, Pizarro A, Wu W, Yocum AK, Seiler C, Pack MA, Blair IA, FitzGerald GA, Grosser T: Analysis of the zebrafish proteome during embryonic development. Mol Cell Proteomics 7(5): 981-94, 2008 Notes: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2401336/
149 Fries S*, Grosser T* [* Co-First Authors], Price TS, Lawson JA, Kapoor S, DeMarco S, Pletcher MT, Wiltshire T, FitzGerald GA: Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130: 55-64, 2006.
2c